AICAR vs GHRP-6

Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide; acadesine) is a non-peptide, cell-permeable nucleoside analog and prodrug that is phosphorylated intracellularly to its monophosphate form (ZMP), which mimics AMP to activate AMP-activated protein kinase (AMPK) — the primary cellular energy sensor — producing metabolic effects that partially phenocopy those of exercise and caloric restriction. AMPK activation by AICAR upregulates GLUT4 expression and glucose uptake, stimulates fatty acid oxidation, increases mitochondrial biogenesis via PGC-1alpha, and suppresses hepatic gluconeogenesis; a landmark 2008 preclinical study demonstrated that AICAR administration in sedentary mice increased running endurance and activated exercise-related gene expression programs without physical training, generating significant research interest in its potential as an exercise mimetic. The only published human clinical trial involved intravenous AICAR administration in patients with type 2 diabetes, where it reduced hepatic glucose output and inhibited whole-body lipolysis via AMPK, validating the pathway pharmacology in humans; the exercise-mimetic effects observed in rodents have not been replicated or evaluated in any human study, and no oral or injectable form has been assessed for human performance use in published research. AICAR is not a peptide and has no FDA approval; it is prohibited in sport by WADA, available only as a research chemical, and all performance-related interest derives from preclinical rodent data that has not been translated to human investigation; the IV metabolic effects in diabetic patients should not be extrapolated to an athletic or performance context.

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 research contexts: GHRP-6 has been studied via subcutaneous and intravenous administration in human and animal research. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection in research contexts. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.